Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gynecologic 2

Conditions

Endometrial Neoplasms 1Cervical Intraepithelial Neoplasia Grade 2/3 1

Interventions

Paclitaxel 192Carboplatin 159pembrolizumab 118Bevacizumab 86liposomal doxorubicin 68Gemcitabine 62Cisplatin 55olaparib 49Topotecan 47Nivolumab 32niraparib 30Cyclophosphamide 30Doxorubicin 29Docetaxel 261-dodecylpyridoxal 22Injections 21Drug Therapy 20human papillomavirus vaccine, L1 type 16, 18 19fludarabine 18atezolizumab 18Pemetrexed 18lenvatinib 17mirvetuximab soravtansine 16Fulvestrant 16avelumab 15Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 15durvalumab 14Oxaliplatin 13Irinotecan 13Fluorouracil 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Cytological Techniques × Gynecologic × Clear all
NCT07148154 2025-08-29

Development of a Non-invasive IVD for Endometrial Cancer Screening on High-risk Populations

MiMARK Diagnostics, S.L.

Recruiting
3,000 enrolled
Gynecologic

Endometrial Neoplasms

NCT03366493 2017-12-08

The Study of Folate Receptor-Mediated Staining Solution (FRDâ„¢) In Cervical Lesion Detection

GY Highland Biotech LLC

Phase 3 Unknown
200 enrolled
Gynecologic

Cervical Intraepithelial Neoplasia Grade 2/3

Data powered by HemOnc (CC BY 4.0) Colophon âš¡